Eton Pharmaceuticals, Inc.
For the period ended Sep 30, 2026. Filed Nov 5, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2026 · Filed Nov 5, 2026
ETON$67.54+5.0%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Statements of Stockholders’ Equity
For the three months ended September 30, 2026 and 2025
(in thousands, except share amounts)
| Common Stock · Additional Paid-inCapital · AccumulatedDeficit · Total Stockholders’Equity | |||||
|---|---|---|---|---|---|
| Shares · Amount | |||||
| Balances at June 30, 2026 | 28,289,941 | $28 | $145,919 | $(99,362) | $46,585 |
| Stock-based compensation | — | — | 3,309 | — | 3,309 |
| Stock option exercises and vesting of restricted stock | 537,964 | 1 | 1,779 | — | 1,780 |
| Net income | — | — | — | 35,249 | 35,249 |
| Balances at September 30, 2026 | 28,827,905 | $29 | $151,007 | $(64,113) | $86,923 |
| Common Stock · Additional Paid-inCapital · AccumulatedDeficit · Total Stockholders’Equity | |||||
|---|---|---|---|---|---|
| Shares · Amount | |||||
| Balances at June 30, 2025 | 26,817,535 | $27 | $135,984 | $(112,050) | $23,961 |
| Stock-based compensation | — | — | 1,092 | — | 1,092 |
| Net loss | — | — | — | (1,927) | (1,927) |
| Balances at September 30, 2025 | 26,817,535 | $27 | $137,076 | $(113,977) | $23,126 |
Condensed Statements of Stockholders’ Equity
For the nine months ended September 30, 2026 and 2025
(in thousands, except share amounts)
| Common Stock · Additional Paid-inCapital · AccumulatedDeficit · Total Stockholders’Equity | |||||
|---|---|---|---|---|---|
| Shares · Amount | |||||
| Balances at December 31, 2025 | 27,047,061 | $27 | $138,621 | $(112,494) | $26,154 |
| Stock-based compensation | — | — | 6,295 | — | 6,295 |
| Stock option exercises and vesting of restricted stock | 1,463,597 | 2 | 5,821 | — | 5,823 |
| Exercise of warrants, net of shares withheld | 296,215 | — | — | — | — |
| Shares issued under employee stock purchase plan (“ESPP”) | 21,032 | — | 270 | — | 270 |
| Net income | — | — | — | 48,381 | 48,381 |
| Balances at September 30, 2026 | 28,827,905 | $29 | $151,007 | $(64,113) | $86,923 |
| Common Stock · Additional Paid-inCapital · AccumulatedDeficit · Total Stockholders’Equity | |||||
|---|---|---|---|---|---|
| Shares · Amount | |||||
| Balances at December 31, 2024 | 26,709,084 | $27 | $132,294 | $(107,893) | $24,428 |
| Stock-based compensation | — | — | 4,388 | — | 4,388 |
| Stock option exercises and vesting of restricted stock | 108,451 | — | 394 | — | 394 |
| Net loss | — | — | — | (6,084) | (6,084) |
| Balances at September 30, 2025 | 26,817,535 | $27 | $137,076 | $(113,977) | $23,126 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.